Stay updated on CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial
Sign up to get notified when there's something new on the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page.

Latest updates to the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoChange DetectedRevision: v3.6.5 replaces v3.6.4, indicating a minor update to the page's platform or content management. This update does not alter the study details or eligibility information presented on the page.SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe page's revision label has been updated to v3.6.4, indicating a minor system or documentation update. No study information or visible content has changed.SummaryDifference0.0%

- Check48 days agoChange DetectedThe page now shows Revision: v3.6.3, replacing v3.6.2. This indicates a minor update to the page content or its documentation without altering the core study information.SummaryDifference0.0%

- Check56 days agoChange DetectedThe page's revision label was updated from v3.6.0 to v3.6.2, indicating a newer software version rather than a change to primary content.SummaryDifference0.0%

- Check71 days agoChange DetectedNew user guidance sections were added and a recruitment status note indicates recruitment has ended. The heading for the intervention section was updated from 'Intervention / Treatment' to 'Intervention/Treatment', and a new revision stamp 'Revision: v3.6.0' appears.SummaryDifference0.3%

- Check78 days agoChange DetectedThe page now displays a new revision label, indicating a minor update to the page template or system. This does not appear to modify any study details or actionable content.SummaryDifference0.0%

Stay in the know with updates to CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page.